TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23211271

Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups held weekly for 12 consecutive weeks, followed by monthly maintenance sessions for a further 7 months.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups for people with dementia and their caregivers.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups for people with dementia who attended more sessions.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups for caregivers who attended more groups.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Health and social care services usage.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Quality-adjusted life-year gains derived from European Quality of Life-5 Dimensions.
Number of subjects: 488
Study: 20573384

Group type: EXPERIMENTAL
Intervention: Bilateral intrafascial nsEERPE (group A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Bilateral standard nsEERPE (group B)
Number of subjects: 400
Study: 19014075

Group type: EXPERIMENTAL
Intervention: Real CPAP
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 102
Study: 15834098

Group type: EXPERIMENTAL
Intervention: 400 mg oral moxifloxacin (two doses with a 12 hour interval)
Number of subjects: 35
Study: 12653425

Group type: EXPERIMENTAL
Intervention: 6-week, low-calorie diet
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 82
Study: 10566928

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) with cuff volumes ranging from 0 to 40 ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA) with cuff volumes ranging from 0 to 60 ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: No airway device (controls)
Number of subjects: 20
Study: 8946925

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Chemotherapy (Chemo)
Number of subjects: 204

Group type: COMPARATOR
Intervention: ASCT
Number of subjects: 204

Group type: COMPARATOR
Intervention: Chemo
Number of subjects: 204
Study: 1768574

Group type: EXPERIMENTAL
Intervention: Tryptophan, given at molar concentrations below those required to stimulate duodenal osmoreceptors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycine, given in concentrations similar to those of levodopa.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa, concentrations not specified.
Number of subjects: 0
Study: 7032340

Group type: EXPERIMENTAL
Intervention: Antigen-free elemental diet (Vivasorb)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control diet (blended ordinary hospital food)
Number of subjects: 41
Study: 29697464

Group type: EXPERIMENTAL
Intervention: Phenytoin/Fosphenytoin
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: Phenytoin/Fosphenytoin vs Levetiracetam
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Seizure history
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Diagnosis of brain tumor
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Temporal craniotomy
Number of subjects: 1916
Study: 29874680

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Relaxation group
Number of subjects: 40
Study: 27502803

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) in addition to neurodevelopmental therapy (NDT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) in addition to neurodevelopmental therapy (NDT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (NDT only)
Number of subjects: 75
Study: 24821594

Group type: EXPERIMENTAL
Intervention: Pyrazinamide MIC ≤ 50 mg/L
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pyrazinamide MIC > 50 mg/L
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard combination therapy (isoniazid, rifampicin, pyrazinamide, ethambutol)
Number of subjects: 58
Study: 22968617

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 0
Study: 20692169

Group type: EXPERIMENTAL
Intervention: Anti-tuberculosis treatment (ATT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Current standard therapies (Control)
Number of subjects: 25
Study: 17464305

Group type: EXPERIMENTAL
Intervention: 360 degrees total capsule cover (group I)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Partial cover (group II)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No cover (group III)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined groups I and II
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group I vs group II
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Quartile change in area of capsule cover
Number of subjects: 150
Study: 15849647

Group type: EXPERIMENTAL
Intervention: Sports medicine class
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (students not participating in the sports medicine class)
Number of subjects: 150
Study: 12500711

Group type: EXPERIMENTAL
Intervention: phenytoin
Number of subjects: 256

Group type: COMPARATOR
Intervention: fosphenytoin
Number of subjects: 256
Study: 9708514

Group type: EXPERIMENTAL
Intervention: 1 mCi/4 ml unfiltered 99mTc‐sulfur colloid injected in four divided doses around the palpable lesion or adjacent to the excision cavity
Number of subjects: 32
Study: 7860458

Group type: EXPERIMENTAL
Intervention: High father involvement (n = 305)
Number of subjects: 985

Group type: COMPARATOR
Intervention: Low father involvement (n = 148)
Number of subjects: 985
Study: 2612167

Group type: EXPERIMENTAL
Intervention: 30 micrograms 3kDOG per 24 hours (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15 micrograms 3kDOG per 24 hours (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 20
Study: 341904

Group type: EXPERIMENTAL
Intervention: Halopredone acetate 0.01%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Halopredone acetate 0.025%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Halopredone acetate 0.05%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Halopredone acetate (all concentrations)
Number of subjects: 0
Study: 30861334

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) + Methotrexate (MTX)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Leflunomide (LEF) + Methotrexate (MTX)
Number of subjects: 75
Study: 28902703

Group type: EXPERIMENTAL
Intervention: Attending school (≥80% school days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dropping out of school
Number of subjects: 0
Study: 26563923

Group type: EXPERIMENTAL
Intervention: Multimodal analgesic (MMA) injection with morphine, ropivacaine, and methylprednisolone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic saline (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 23510018

Group type: EXPERIMENTAL
Intervention: Switch to the highest approved dose of rosuvastatin (40 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Add-on extended release nicotinic acid (ER-NA)/l-aropiprant (LRPT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Add-on micronised fenofibrate
Number of subjects: 100
Study: 20706728

Group type: EXPERIMENTAL
Intervention: Flaxseed oil capsules (11 g/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (2 g/day + 9 g/day of olive oil)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Olive oil capsules (11 g/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 59
Study: 19936516

Group type: EXPERIMENTAL
Intervention: 10% Lippia Sidoides (LS) gel
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo gel (control group)
Number of subjects: 23
Study: 17963876

Group type: EXPERIMENTAL
Intervention: EUS examination
Number of subjects: 206
Study: 15272397

Group type: EXPERIMENTAL
Intervention: ALVAC‐HIV (vCP1521) and AIDSVAX B/E
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E (600 microg)
Number of subjects: 133
Study: 11299133

Group type: EXPERIMENTAL
Intervention: Sertraline 100mg per day for 2 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 11
Study: 9882034

Group type: EXPERIMENTAL
Intervention: Empirical treatment with omeprazole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prompt endoscopy followed by directed medical treatment
Number of subjects: 80
Study: 7912879

Group type: EXPERIMENTAL
Intervention: Clomipramine + dixyrazine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clomipramine + placebo
Number of subjects: 45
Study: 2803882

Group type: EXPERIMENTAL
Intervention: Bupivacaine with fentanyl (loading dose of 0.5% bupivacaine 6.0 ml and fentanyl 100 micrograms, followed by infusion of 0.08% bupivacaine 15 ml h‐1 plus fentanyl 37.5 micrograms h‐1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bupivacaine alone (loading dose of 0.5% bupivacaine 6.0 ml and saline 2.0 ml, followed by infusion of 0.08% bupivacaine alone)
Number of subjects: 39
Study: 4827462

Group type: EXPERIMENTAL
Intervention: 2.5 mg/70 kg heroin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg/70 kg heroin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TLC procedures with hydrolysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FRAT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RIA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Technicon Autoanalyzer
Number of subjects: 10
Study: 31620896

Group type: EXPERIMENTAL
Intervention: HPP/target therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 62
Study: 30839090

Group type: EXPERIMENTAL
Intervention: DWt + 400 mg/L of PLG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DWt + 400 mg/L of LBS
Number of subjects: 180

Group type: COMPARATOR
Intervention: DWt control (without MOO)
Number of subjects: 180
Study: 27698102

Group type: EXPERIMENTAL
Intervention: Immediate-start intervention group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed-start intervention group (Control)
Number of subjects: 80
Study: 24885592

Group type: EXPERIMENTAL
Intervention: Translation (TR) load
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Controlled tipping (CT) load
Number of subjects: 21
Study: 23498096

Group type: EXPERIMENTAL
Intervention: Computer-delivered tailored CRC screening intervention
Number of subjects: 693

Group type: COMPARATOR
Intervention: Nontailored informational brochure about CRC screening
Number of subjects: 693
Study: 21346110

Group type: EXPERIMENTAL
Intervention: Oral Fat Tolerance Test (OFTT: 1 g lipid/kg body weight) followed by caffeinated coffee (5 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee and decaffeinated coffee
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 19233423

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (1 gm, 10% weight per weight, ethanol based formulation) once daily for 12 weeks
Number of subjects: 789

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 789
Study: 16391591

Group type: COMPARATOR
Intervention: Combination treatment (glucomannan and plant sterols)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glucomannan
Number of subjects: 34
Study: 12175635

Group type: EXPERIMENTAL
Intervention: C4AQ0 alleles observed in 45/73 (62%) NR
Number of subjects: 4269

Group type: EXPERIMENTAL
Intervention: C4ADel observed in 24/73 (33%) NR
Number of subjects: 4269

Group type: EXPERIMENTAL
Intervention: C4AQ0 alleles present in 21/49 (43%) NR without C4Del
Number of subjects: 4269
Study: 10048740

Group type: EXPERIMENTAL
Intervention: Early postoperative enteral nutrition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative CMI score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Change in immunologic status from responding to anergy postoperatively
Number of subjects: 60
Study: 7727966

Group type: EXPERIMENTAL
Intervention: Leukocyte‐depleted blood components (platelet concentrates and packed red cells)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard platelet concentrates and leukocyte‐depleted packed red cells (control group)
Number of subjects: 52
Study: 1943932

Group type: EXPERIMENTAL
Intervention: Vitamin B1 and/or diuretics treatment for alcohol-related cardiomyopathy
Number of subjects: 1309
Study: 7005293

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray (300 micrograms/day or less)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 6432595

Group type: EXPERIMENTAL
Intervention: beta-carotene/canthaxanthin
Number of subjects: 2

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study: 29926675

Group type: EXPERIMENTAL
Intervention: Brisk walking group A (10,000-12,000 steps/day for 16 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brisk walking group B (10,000-12,000 steps/day for first 10 weeks, 14,000-15,000 steps/day for last 6 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group C (normal living conditions)
Number of subjects: 80
Study: 26559156

Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable intake among individuals with high processed meat intakes
Number of subjects: 0
Study: 24774437

Group type: EXPERIMENTAL
Intervention: Posturographic platform biofeedback training (forced sway training) for 15 consecutive days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional rehabilitation (control group)
Number of subjects: 21
Study: 22894747

Group type: EXPERIMENTAL
Intervention: IT-based intervention (website and mobile phone)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Print-based intervention
Number of subjects: 317
Study: 20211041

Group type: EXPERIMENTAL
Intervention: Isomaltulose (iso; Palatinose)
Number of subjects: 0
Study: 19023446

Group type: EXPERIMENTAL
Intervention: Librarian information (JIT service)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No librarian information (control group)
Number of subjects: 88
Study: 16079422

Group type: EXPERIMENTAL
Intervention: Educational intervention (educational pamphlet based on current evidence)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (standard nondirected discharge information sheet)
Number of subjects: 112
Study: 11943797

Group type: EXPERIMENTAL
Intervention: Screening for abdominal aortic aneurysm
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Active follow up every 3 months for men with an aortic diameter of 45-54 mm
Number of subjects: 2342
Study: 10520573

Group type: EXPERIMENTAL
Intervention: Testosterone patches (5 mg testosterone over 24 hours)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HIV-infected men with weight loss (5 lb or more)
Number of subjects: 148

Group type: COMPARATOR
Intervention: HIV-infected men without weight loss
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HIV-infected men
Number of subjects: 148

Group type: COMPARATOR
Intervention: HIV-infected men with serum testosterone levels < 400 ng/dL
Number of subjects: 148
Study: 7669218

Group type: EXPERIMENTAL
Intervention: Fluoride-sucrose solution (1 mg/kg, 5 mg/kg, 10 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sucrose solution (control)
Number of subjects: 6
Study: 2187695

Group type: EXPERIMENTAL
Intervention: Weight loss diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced sodium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss plus reduced sodium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced sodium plus increased potassium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 0
Study: 7030902

Group type: EXPERIMENTAL
Intervention: Heptavax B vaccine (40 micrograms each, three doses)
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Heptavax B vaccine
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study: 31495380

Group type: EXPERIMENTAL
Intervention: Low-frequency use (approximately 1 day/week)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Persistent frequent use (approximately 4 days/week)
Number of subjects: 720
Study: 29156875

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1 mg/kg IV 1 hour before anesthesia)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 392
Study: 26529601

Group type: EXPERIMENTAL
Intervention: 1.5 g of calcium HMB for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no HMB supplementation)
Number of subjects: 80
Study: 23379828

Group type: EXPERIMENTAL
Intervention: Internal fixation with 2 cannulated compression screws combined with an iliac graft (n=44)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Internal fixation with 3 cannulated compression screws (n=34)
Number of subjects: 78
Study: 21696115

Group type: EXPERIMENTAL
Intervention: Begg retainers
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Essix retainers
Number of subjects: 224

Group type: COMPARATOR
Intervention: Both retainers
Number of subjects: 224
Study: 19232793

Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: High glycemic index diet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 16
Study: 17360095

Group type: EXPERIMENTAL
Intervention: Group 3 ('school') - medical students teaching BLS to school children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group 2 ('EMS') - accompanied a BLS vehicle of the emergency medical service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group 1 ('university') - attended a conventional university BLS/ALS course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group 1 ('university')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group 2 ('EMS')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 3 ('school')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group 1 ('university') and Group 2 ('EMS')
Number of subjects: 0
Study: 15145964

Group type: EXPERIMENTAL
Intervention: St. John's wort (300 mg tablet, three times daily for 14 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 12
Study: 12528954

Group type: EXPERIMENTAL
Intervention: Optibond Fl (Kerr)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose (3M)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus (Kerr)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Single Bond (3M)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fourth-generation adhesive resin systems (filled and unfilled)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fifth-generation adhesive resin systems (filled and unfilled)
Number of subjects: 80
Study: 10430427

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.75 mg, titrated to a maximum of 24 mg)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Bromocriptine (1.25 mg, titrated to a maximum of 40 mg)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 335

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 335
Study: 10150437

Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 208

Group type: COMPARATOR
Intervention: CO2 laser ablation
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Electrosurgery and CO2 laser ablation
Number of subjects: 208
Study: 1646621

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg) and felodipine ER (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Felodipine monotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapy (Ramipril and Felodipine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 12
Study: 6950685

Group type: EXPERIMENTAL
Intervention: Cranial irradiation plus 5 doses of i.t. MTX
Number of subjects: 61

Group type: COMPARATOR
Intervention: One dose of i.t. MTX after induction, repeated every 3 months
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: BCG therapy by scarification
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Not applicable (initial relapses)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Not applicable (mortality)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Not applicable (survival rates)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Not applicable (long-term remission)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Not applicable (CNS relapses)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 61
Study: 31999743

Group type: EXPERIMENTAL
Intervention: deprexis (tailored, integrative digital intervention)
Number of subjects: 2901
Study: 29319497

Group type: EXPERIMENTAL
Intervention: Tigecycline plus high-dose cefoperazone-sulbactam (1:1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tigecycline monotherapy
Number of subjects: 42
Study: 25101831

Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM) lipid-based formulation in gelatin capsules coated with Eudragit® S100
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zocor® tablets (reference control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM) lipid-based formulation
Number of subjects: 0
Study: 24718367

Group type: EXPERIMENTAL
Intervention: Prasugrel 60-mg or 30-mg loading dose (LD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel 600-mg loading dose (LD)
Number of subjects: 0